Medincell Continues to Strengthen and Renew its Board of Directors with the Proposed Appointment of Dr. Elisabeth Svanberg
The Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at Medincell's upcoming Annual General Meeting
Upon her election, 50% of Medincell's Board will have been renewed since 2025, strengthening expertise in innovation, pharmaceutical development, governance, executive compensation and global health
Dr. Svanberg is expected to be named by the Board as Chair of Medincell's Remuneration & Nomination Committee, subject to her election as a director by the shareholders
Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at the Company's Annual General Meeting on September 30, 2026. A highly experienced international life sciences executive, Dr. Svanberg would bring deep expertise in global pharmaceutical development, governance, executive compensation and global health as Medincell advances its next phase of growth.
